Pegylated Interferon Alpha2A
Breast Tumor
BriaCell Therapeutics CorporationPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Breast Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bc1 cell line BriaCell Therapeutics Corporation | Phase 1/2 | CCC |
Tislelizumab BriaCell Therapeutics Corporation | Phase 1/2 | CCC |
Nuv-868 Nuvation Bio Inc. | Phase 1 | CC |
68Ga-NOTA-RM26 Peking Union Medical College Hospital | Early Phase 1 | C |
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine Nuvation Bio Inc. | Phase 1/2 | C |
Desflurane Zhongnan Hospital | N/A | D |
Same molecule, other indications
Pegylated Interferon Alpha2A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →